Is the duration of adjuvant trastuzumab debate still clinically relevant?
The selection of optimal systemic therapy for early HER2-positive breast cancer has become exceedingly complex. Since the advent of adjuvant trastuzumab, several new drugs have shown substantial incremental benefits.
1- 4 Clearly, not all patients should receive these additional therapies. Hence, it is incumbent upon clinicians to carefully select patients who are the most likely to benefit from an escalation strategy. To this end, progress is being made. For example, the recognition that poor response to neoadjuvant therapy is associated with poor outcomes in HER2-positive disease led to the design of the KATHERINE study, 5 in which patients with residual disease after neoadjuvant therapy received adjuvant trastuzumab-emtansine or standard trastuzumab. The 3-year absolute invasive-disease-free survival was improved by more than 10 percentage points (88·3% with trastuzumab-emtansine and 77·0% with trastuzumab; hazard ratio [HR] 0·50, 95% CI 0·39-0·64), akin to the remarkable benefits observed in the first adjuvant trastuzumab studies. 6, 7 Conversely, advances have also been made with respect to de-escalating therapy for HER2-positive early disease. In the past decade, multiple trials, including two phase 3 randomised trials, 7, 8 one three-group phase 2 trial, 2 and two single-group phase 2 trials, 9, 10 have found an excellent therapeutic index associated with novel, anthracycline-free regimens. Additionally, five studies [11] [12] [13] [14] [15] [16] evaluated whether a shorter duration of trastuzumab is non-inferior to the standard year. Non-inferiority could not be concluded in the first four studies; [11] [12] [13] [14] thus, the debate appeared to be closed. In The Lancet, results from the two largest trials to address length of trastuzumab treatment-PERSEPHONE, done by Helena Earl and colleagues, 15 and PHARE, done by Xavier Pivot and colleagues 16 are reported. The authors of both studies should be congratulated on these well planned, academically run, important trials, which were similarly designed and found HRs that were nearly equivalent. However, the conclusions drawn from each are entirely discordant. Understanding these seemingly contradictory interpretations requires a closer look at the endpoints chosen.
The phase 3 French study PHARE 16 enrolled over 3300 patients. In 2012, an unplanned analysis 13 done at the bequest of the Independent Data Monitoring Committee with 394 disease-free-survival events could not show non-inferiority for 6 months of trastuzumab treatment (HR 1·28, 95% CI 1·05-1·56; p=0·29) with a prespecified non-inferiority margin of 1·15. As reported in The Lancet, final results from PHARE, 16 with a median follow-up of 7·5 years and 704 disease-free-survival events, confirm that non-inferiority cannot be claimed for a shorter duration of trastuzumab treatment, as the adjusted HR was 1·08 (95% CI 0·93-1·25), which included the non-inferiority margin of 1·15.
On the other hand, the phase 3 UK study PERSEPHONE 15 enrolled over 4000 patients and, with median follow-up of 5·4 years and 512 disease-freesurvival events, found a 4-year disease-free survival of 89·4% (95% CI 87·9-90·7) for 6-month treatment and 89·8% (95% CI 88·3-91·1) for 12-month treatment (HR 1·07, 90% CI 0·93-1·24). This outcome is consistent with non-inferiority according to the prespecified non-inferiority margin of less than 3%, HR 1·32. While the HRs and CIs for the two studies were close, one is interpreted as having met non-inferiority and the other is not, all because of where the margin was set. As Pivot and colleagues 16 point out, although guidance on the selection of non-inferiority margins now exists, the subject of what constitutes an acceptable margin for equivalence, especially in a setting where the goal is to achieve remission from an aggressive form of cancer, is quite subjective and hence, debatable.
When trying to decipher discordant results from similarly designed trials, it is natural to refer to the subgroup analysis for answers. This practice can, of course, lead to inappropriate conclusions. In PERSEPHONE, 15 heterogeneity favouring 12 months of treatment was noted for patients who had nonanthracycline treatment, had concurrent chemotherapy and trastuzumab treat ment, and had oestrogenreceptor-negative tumours. The initial results from PHARE 13 also suggested heterogeneity favouring 12 months of treatment in oestrogen-receptor-negative tumours but, in contrast to PERSEPHONE, suggested that patients treated with sequential chemotherapy and trastuzumab derived more benefit from 12 months of treatment. However, in Pivot and colleagues' final analysis 16 reported in The Lancet, the heterogeneity noted in the interim analysis of PHARE 13 entirely disappeared, underscoring both the need for caution when interpreting subgroups and the importance of longer-term follow-up. Longer follow-up might be particularly important for patients whose disease is oestrogen-receptor positive, as disease-free-survival events could occur later. 17 In considering the HR from both studies, it is important to note that the likelihood of benefit with 12 months of trastuzumab treatment compared with 6 months of treatment is small. Undoubtedly, a shorter duration of trastuzumab might be appropriate for some patients with lower-risk disease, without concern for diminished benefit. That said, a possible way to improve upon the therapeutic index for adjuvant trastuzumab might be the use of an anthracycline-free regimen, with which the risk of symptomatic cardiomyopathy is approximately 0·5%. 7, 9, 10 Despite the fact that patients enrolled in PHARE and PERSEPHONE had quite good prognostic features, anthracycline-based treatment was given to 90% of patients, thus increasing the risk of cardiac toxicity. Neither PERSEPHONE nor PHARE adequately address the noninferiority or safety of the shorter duration of trastuzumab treatment when given with an anthracycline-free regimen, which begs the question: are studies evaluating shorter duration trastuzumab with anthracycline-free regimens really worthwhile, when the risks of adjuvant trastuzumab in this setting are so low? As the authors of PHARE note, "Without any safety concerns related to adjuvant trastuzumab, a pharmacoeconomic model of the cost savings with a shorter treatment duration seems to be the criterion supporting the decrease in duration". 16 In future years, it will indeed be important to follow the data of PERSEPHONE as they mature. Moreover, a meta-analysis of all studies with long-term follow-up evaluating duration of trastuzumab will be informative. In an era in which non-anthracycline-based regimens are increasingly being used, and our ability to risk-stratify patients for the selection of additional therapies has improved, the benefit, if any, of reducing the duration of trastuzumab is not clear.
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